Global Oligonucleotide CDMO Market Growth (Status and Outlook) 2025-2031

The global Oligonucleotide CDMO market size is predicted to grow from US$ 1370 million in 2025 to US$ 2847 million in 2031; it is expected to grow at a CAGR of 13.0% from 2025 to 2031.

An Oligonucleotide CDMO (Contract Development and Manufacturing Organization) specializes in providing outsourced services related to the development and manufacturing of oligonucleotides. Oligonucleotides are short DNA or RNA molecules used for a variety of applications, including in genetic research, diagnostics, and therapeutics. These organizations are key players in the biopharmaceutical industry, helping companies bring oligonucleotide-based products from the research stage to commercialization.

United States market for Oligonucleotide CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Oligonucleotide CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Oligonucleotide CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Oligonucleotide CDMO players cover Agilent, ST Pharm, Bachem, BioSpring, Creative Biogene, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Oligonucleotide CDMO Industry Forecast” looks at past sales and reviews total world Oligonucleotide CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Oligonucleotide CDMO sales for 2025 through 2031. With Oligonucleotide CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oligonucleotide CDMO industry.

This Insight Report provides a comprehensive analysis of the global Oligonucleotide CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oligonucleotide CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oligonucleotide CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oligonucleotide CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oligonucleotide CDMO.

This report presents a comprehensive overview, market shares, and growth opportunities of Oligonucleotide CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type:
APIs and Intermediates
FDF

Segmentation by Application:
Pharmaceutical and Biotechnology Companies
Research Institutes
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Agilent
ST Pharm
Bachem
BioSpring
Creative Biogene
Sylentis
Ajinomoto Bio-Pharma
EUROAPI
Veliter
PolyPeptide Group
CordenPharma
Thermofischer
Bio Basic
Genscript
Cytiva
ScinoPharm
CBL
Piramal Pharma
CPC Scientific
Eurogentec
Cambrex
WuXi STA

Please note: The report will take approximately 2 business days to prepare and deliver.